Brainsway (BWAY) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BrainsWay has unveiled promising clinical data from a study showing that its Deep Transcranial Magnetic Stimulation therapy significantly reduces pain as well as symptoms of anxiety and depression in patients with chronic peripheral neuropathic pain. The findings, published in the Neuromodulation journal, highlight the potential of Deep TMS as an effective noninvasive treatment option, although it is not yet FDA-approved for neuropathic pain. This could bolster investor interest as the company expands its portfolio of mental health disorder treatments.
For further insights into BWAY stock, check out TipRanks’ Stock Analysis page.
